Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CORT Corcept Therapeutics

Closed 08-06 16:00:00 EDT

107.95

-2.74

-2.48%

盘后107.95

+0.000.00%

19:34 EDT

High111.00	Low107.32	Vol761.83K
Open111.00	D1 Closing110.69	Amplitude3.32%
Mkt Cap11.67B	Tradable Cap9.79B	Total Shares108.10M
T/O82.38M	T/O Rate0.84%	Tradable Shares90.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CORT","market":"US","secType":"STK","nameCN":"Corcept Therapeutics","latestPrice":107.95,"timestamp":1786046400000,"preClose":110.69,"halted":0,"volume":761834,"hourTrading":{"tag":"盘后","latestPrice":107.95,"preClose":107.95,"latestTime":"19:34 EDT","volume":20252,"amount":2186207.3517,"timestamp":1786059242594,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02475381696630224,"floatShares":90688200,"shares":108098397,"eps":0.453654,"marketStatus":"Closed","change":-2.74,"latestTime":"08-06 16:00:00 EDT","open":111,"high":111,"low":107.32,"amount":82375841.204556,"amplitude":0.033246,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.453654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1786089600000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1081915200000,"exchange":"NASDAQ","adjPreClose":110.69,"preHourTrading":{"tag":"盘前","latestPrice":110,"preClose":110.69,"latestTime":"09:26 EDT","volume":84,"amount":9534.449400000001,"timestamp":1786022810695,"change":-0.69,"changeRate":-0.006234,"amplitude":0.034149},"postHourTrading":{"tag":"盘后","latestPrice":107.95,"preClose":107.95,"latestTime":"19:34 EDT","volume":20252,"amount":2186207.3517,"timestamp":1786059242594,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.375627,"impliedVol":0.4897,"impliedVolPercentile":0.2709},"requestUrl":"/m/hq/s/CORT","defaultTab":"news","newsList":[{"id":"2657656597","title":"Corcept Therapeutics (CORT) Stock Could Be Undervalued Despite Mixed Broader Checks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656597","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656597?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:39","pubTimestamp":1786030757,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics stock has delivered a very large 5 year return, yet its recent valuation checks suggest the shares are not an obvious bargain at today's level.\n\nOver the past 5 years, Corcept Therapeutics has returned about 4.4x, which sets a high bar for any further upside to be justified by fundamentals.\nInvestor focus is currently on how demand for the company’s treatments and late stage pipeline can support future revenue, while execution and clinical outcomes across those programs...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/corcept-therapeutics-cort-stock-could-be-undervalued-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0566484027.USD","PSCH","CORT","LU1559883803.SGD","FBT","BK4007","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571260","title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571260","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571260?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:11","pubTimestamp":1785967865,"startTime":"0","endTime":"0","summary":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon disposes of 1,540 common shares worth $175,806.40Corcept Therapeutics Chief Accounting & Technology Officer Joseph Douglas Lyon sold 1","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4ffvrh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon Disposes of 1,540 Common Shares Worth $175,806.40","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","FBT","BK4532","CORT","LU0566484027.USD","BK4007","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544649","title":"We Think That There Are More Issues For Corcept Therapeutics (NASDAQ:CORT) Than Just Sluggish Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544649","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544649?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:29","pubTimestamp":1785929370,"startTime":"0","endTime":"0","summary":"Following the release of a lackluster earnings report from Corcept Therapeutics Incorporated ( NASDAQ:CORT ) the stock...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/we-think-that-there-are-more-issues-for-corcept-therapeutics","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/we-think-that-there-are-more-issues-for-corcept-therapeutics","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656556721","title":"Why Corcept Therapeutics (CORT) Is Up 19.8% After Boosting 2026 Revenue Guidance And Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2656556721","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656556721?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:25","pubTimestamp":1785842712,"startTime":"0","endTime":"0","summary":"In late July 2026, Corcept Therapeutics reported second-quarter net income of US$42.99 million, up from US$35.15 million a year earlier, with diluted earnings per share from continuing operations rising to US$0.36 from US$0.29.\nAlongside these stronger quarterly profits, the company raised its full-year 2026 revenue guidance to between US$1.1 billion and US$1.2 billion, signalling management’s confidence in its business momentum.\nWe’ll now examine how Corcept’s upgraded 2026 revenue guidance...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/why-corcept-therapeutics-cort-is-up-198-after-boosting-2026","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cort/corcept-therapeutics/news/why-corcept-therapeutics-cort-is-up-198-after-boosting-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304023","title":"Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304023","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304023?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:40","pubTimestamp":1785789635,"startTime":"0","endTime":"0","summary":"Corcept CFO Atabak Mokari sells 79,000 shares worth $8.95 millionCorcept Therapeutics CFO Atabak Mokari exercised stock options for 80,000 shares at USD 23.06 on July 30, 2026.He sold 79,870 shares th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL58BTGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Corcept CFO Atabak Mokari Sells 79,000 Shares Worth $8.95 Million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1559883803.SGD","BK4532","LU0566484027.USD","FBT","PSCH","CORT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656430313","title":"3 High Growth Stocks Investors May Be Missing Right Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2656430313","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656430313?lang=en_us&edition=fundamental","pubTime":"2026-08-03 03:22","pubTimestamp":1785698528,"startTime":"0","endTime":"0","summary":"Global markets are wrestling with higher energy prices, sticky inflation and shifting rate expectations across the US, UK and Eurozone. In this kind of backdrop, investors often look for companies that can grow earnings even when the macro story feels messy. The Healthy high growth potential screener focuses on stocks that analysts expect to deliver strong earnings growth over the next 3 years and that also sit in an acceptable financial position. This article highlights 3 of the best stocks...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/3-high-growth-stocks-investors-may-be-missing-right-now","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/3-high-growth-stocks-investors-may-be-missing-right-now","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VOTE","VGFPF","BK4532","GXDW","BK4539","BK4211","LU0566484027.USD","BK4204","LU1559883803.SGD","JOYT","BK4154","FEBU","CORT","PSCH","RGLO","BK4592","ISBC","COUR","ALHC","BK4007","DECU","FBT","PMDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656127323","title":"Coursera Stock And 2 More Growth Picks Backed By Healthy Balance Sheets","url":"https://stock-news.laohu8.com/highlight/detail?id=2656127323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656127323?lang=en_us&edition=fundamental","pubTime":"2026-08-02 15:22","pubTimestamp":1785655346,"startTime":"0","endTime":"0","summary":"Global markets feel pulled between firm inflation, shifting central bank signals and uneven growth data. Bond yields in the US, UK and Europe keep pressure on valuations, while export powerhouses like South Korea highlight how specific growth stories can still stand out. In this mix, many investors seek companies where analysts see healthy earnings growth potential and balance sheets that look resilient. That is what the Healthy high growth potential screener targets. In this article, you...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6034000-choice2-main-header/1585187286151"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/coursera-stock-and-2-more-growth-picks-backed-by-healthy-bal","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-alhc/alignment-healthcare/news/coursera-stock-and-2-more-growth-picks-backed-by-healthy-bal","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4154","ALHC","VOTE","LU0566484027.USD","PMDE","BK4532","BK4539","BK4007","PSCH","BK4592","CORT","DECU","BK4204","FBT","COUR","LU1559883803.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656318473","title":"OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2656318473","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656318473?lang=en_us&edition=fundamental","pubTime":"2026-08-01 17:01","pubTimestamp":1785574877,"startTime":"0","endTime":"0","summary":"Analysts are intrested in these 5 stocks: ( ($OTLK) ), ( ($HBAN) ), ( ($CORT) ), ( ($CAPR) ) and ( ($GOSS) ). Here is a breakdown of their recent","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/otlk-hban-cort-capr-goss-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/otlk-hban-cort-capr-goss-trending-with-analysts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAPR","LU0029874061.USD","HBAN","BK4532","LU0154245673.USD","LU0566484027.USD","BK4007","BK4585","PSCH","BK4550","BK4139","FBT","CORT","LU0128526141.USD","BK4211","LU1989772840.SGD","OTLK","BK4588","LU1989772923.USD","LU1559883803.SGD","LU0154245756.USD","GOSS","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656955163","title":"LIVE Markets-us Earnings Forecast Jumps Further After Key Reports This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2656955163","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656955163?lang=en_us&edition=fundamental","pubTime":"2026-08-01 02:18","pubTimestamp":1785521930,"startTime":"0","endTime":"0","summary":"THE CLOCK IS TICKING CLICK HERECHERRIES ON THE CAKE: UMICH, EMPLOYMENT COSTS, CHICAGO PMICLICK HEREWALL STREET STOCKS EDGE LOWER AS APPLE DROPS, YIELDS RISECLICK HERETHE BREADTH TRADE'S LATEST PLOT TWIST: BIG TECH ROARS BACKCLICK HEREHOW BOND VIGILANTISM CAN HIT STOCKSCLICK HEREHALF-TIME IN EUROPE: SLOWING MOMENTUMCLICK HEREAI BULLS AND BEARSCLICK HEREWINNERS AND LOSERS OF THE YEAR SO FARCLICK HERERECORDS ALL AROUNDCLICK HEREEUROPE BEFORE THE BELL: GRINDING HIGHER AT MONTH-ENDCLICK HEREYEN SINKS AS BOJ HOLDS - AND IT'S THE KOSPI'S BEST DAYCLICK HERE","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL6N43X17Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","TYLG","XDAT","FRNW","IXN","AMD","BNGE","XSD","HYDR","RKT","VOX","XNTK","HULL","LTL","REZI","RKTL","TTEQ","TTXU","ILMN","GOOGL","IBAT","ROM","FTEC","METV","GXPC","ONLN","CORT","RDTL","ILDR","USAW.SI","ALAB","EFIV","QQQA","RDYY","RTH","AMZN","ARTY","XLK","BE","RDDT","USXF","OGIG","EA","MSFT","TEK","TDIV","XLC","EGGY","FAI","FCOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163426208","title":"Movement Alert｜Corcept Therapeutics Falls 5.04% in Regular Trading, Profit-Taking After Prior Session Earnings-Driven Surge Amid Broad Pharma Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1163426208","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163426208?lang=en_us&edition=fundamental","pubTime":"2026-07-31 22:58","pubTimestamp":1785509932,"startTime":"0","endTime":"0","summary":"On July 31, Corcept Therapeutics declined 5.04% in regular trading, trading at $112.445/share, with turnover of $44.99 million. The pullback follows the stock's approximately 16% surge in the prior...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655365555","title":"Workday Stock And 2 Software Picks Backed By Insider Confidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2655365555","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655365555?lang=en_us&edition=fundamental","pubTime":"2026-07-31 19:27","pubTimestamp":1785497243,"startTime":"0","endTime":"0","summary":"Global growth signals look uneven, inflation trends are mixed, and central banks are keeping investors on their toes. In this kind of backdrop, many readers are looking for companies where management is financially aligned with shareholders and where analysts still see room for growth. That is exactly what the Fast Growing Stocks With High Insider Ownership screener aims to surface. It focuses on businesses with strong growth potential and confident insider backing. In this article you will...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/23815047-main-header/1756202856990","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/23815047-main-header/1756202856990"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-wday/workday/news/workday-stock-and-2-software-picks-backed-by-insider-confide","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-wday/workday/news/workday-stock-and-2-software-picks-backed-by-insider-confide","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QTOC","BK4548","CHAT","BK4007","BK4532","LU1559883803.SGD","LU1935042991.SGD","LU0719512351.SGD","LU1235294995.USD","FBT","LU2265009873.SGD","BK4528","AIPO","LU0082616367.USD","LU1046421795.USD","LU0314104364.USD","WDAY","IE00B5949003.HKD","IE0004445239.USD","LU1691799644.USD","VTHR","LU1804176565.USD","BK4585","LU1823568750.SGD","ARTY","BK4023","LU1989773731.SGD","BK4613","LU1989763005.USD","PSCH","CORT","BK4581","IE0009356076.USD","BK4588","LU2517655374.HKD","LU0566484027.USD","LU2517655291.USD","LU2517655028.SGD","KVYO","LU1935043536.SGD","AGIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655379800","title":"Corcept Therapeutics Price Target Raised to $165.00/Share from $88.00 by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2655379800","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655379800?lang=en_us&edition=fundamental","pubTime":"2026-07-31 02:25","pubTimestamp":1785435900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CORT/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655805550","title":"Corcept Therapeutics Shares Rally After Revenue Guidance Raised","url":"https://stock-news.laohu8.com/highlight/detail?id=2655805550","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655805550?lang=en_us&edition=fundamental","pubTime":"2026-07-30 22:09","pubTimestamp":1785420540,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics's shares hit a 52-week high Thursday after the commercial-stage medications developer lifted its full-year revenue guidance following a strong quarter for its oncology and Cushing","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198111019","title":"Movement Alert｜Corcept Therapeutics Rises 15.98% in Regular Trading, Q2 Earnings Massively Beat Expectations with Raised Full-Year Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1198111019","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198111019?lang=en_us&edition=fundamental","pubTime":"2026-07-30 21:47","pubTimestamp":1785419265,"startTime":"0","endTime":"0","summary":"On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.The surge was driven by the company's Q2 earnings report released after...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655287772","title":"Disc Medicine Posts Smaller-than-expected Q2 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2655287772","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655287772?lang=en_us&edition=fundamental","pubTime":"2026-07-30 20:39","pubTimestamp":1785415190,"startTime":"0","endTime":"0","summary":"Disc Medicine posts smaller-than-expected Q2 net lossOverviewUS biopharma firm's Q2 net loss and operating income both beat analyst expectationsQ2 loss per share was better than expectedOperating expe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0T2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","PSCH","BK4007","CORT","FBT","IRON","BK4532","LU1559883803.SGD","AVXL","LU0053671581.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655987926","title":"Phathom Pharmaceuticals Q2 Revenue Beats on Voquezna Prescription Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2655987926","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655987926?lang=en_us&edition=fundamental","pubTime":"2026-07-30 19:18","pubTimestamp":1785410307,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Q2 revenue beats on Voquezna prescription growthOverviewUS biopharma firm's Q2 revenue rose 88% yr/yr, beating analyst expectationsQ2 operating expenses fell 33% yr/yr due to l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nL1N43W0KS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE00B894F039.SGD","LU0109394709.USD","PBE","LU0889565916.HKD","CORT","BK4007","IE00B19Z9P08.USD","BK4588","BK4532","LU1559883803.SGD","FBT","BMED","LU0320765992.SGD","PSCH","IE00B19Z9Z06.USD","LU0234570918.USD","BIIB","BK4139","BK4585","LU0566484027.USD","PHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878009","title":"Corcept Therapeutics price target raised to $165 from $95 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878009?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:16","pubTimestamp":1785406604,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Corcept Therapeutics (CORT) to $165 from $95 and keeps a Buy rating on the shares. The firm says ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-165-from-95-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/corcept-therapeutics-price-target-raised-to-165-from-95-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148254432","title":"Premarket Movers | CORT Surges 26% as Q2 Earnings Easily Beat Expectations and Full-Year Guidance Is Raised","url":"https://stock-news.laohu8.com/highlight/detail?id=1148254432","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148254432?lang=en_us&edition=fundamental","pubTime":"2026-07-30 16:05","pubTimestamp":1785398708,"startTime":"0","endTime":"0","summary":"On July 30, Corcept Therapeutics rose 20.48% in pre-market trading, trading at $111.11/share, with turnover of $80,100.The surge was driven by the company's Q2 earnings release, which dramatically...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Corcept Therapeutics Pre-Market Rise 26%, Q2 Earnings Massively Beat Expectati...","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CORT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655282910","title":"Corcept Therapeutics Inc : Canaccord Genuity Raises Target Price to $161 from $150","url":"https://stock-news.laohu8.com/highlight/detail?id=2655282910","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655282910?lang=en_us&edition=fundamental","pubTime":"2026-07-30 15:55","pubTimestamp":1785398154,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1F1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","LU1559883803.SGD","CORT","LU0566484027.USD","PSCH","FBT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782580","title":"Corcept Therapeutics (CORT) Stock Soars 22% After Hours: Here's What You Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782580","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655782580?lang=en_us&edition=fundamental","pubTime":"2026-07-30 14:48","pubTimestamp":1785394133,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics shares soared 21.95% after hours as strong quarterly results and raised guidance boosted investor confidence.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/26/07/60787510/corcept-therapeutics-shares-surge-after-hours-q2-results-raised-guidance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","RSI","NUWE","CORT","BK4082","LU0566484027.USD","BK4150","FBT","PSCH","BK4007","LU1559883803.SGD","ODDZ","BETZ","ODDS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.corcept.com","stockEarnings":[{"period":"1week","weight":0.1909},{"period":"1month","weight":0.2083},{"period":"3month","weight":1.1683},{"period":"6month","weight":1.711},{"period":"1year","weight":0.5712},{"period":"ytd","weight":2.1807}],"compareEarnings":[{"period":"1week","weight":0.0553},{"period":"1month","weight":0.0246},{"period":"3month","weight":0.0522},{"period":"6month","weight":0.1146},{"period":"1year","weight":0.2258},{"period":"ytd","weight":0.1289}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.022337},{"month":2,"riseRate":0.409091,"avgChangeRate":0.008661},{"month":3,"riseRate":0.772727,"avgChangeRate":0.140734},{"month":4,"riseRate":0.545455,"avgChangeRate":0.005665},{"month":5,"riseRate":0.521739,"avgChangeRate":0.028192},{"month":6,"riseRate":0.478261,"avgChangeRate":0.048323},{"month":7,"riseRate":0.478261,"avgChangeRate":0.007526},{"month":8,"riseRate":0.391304,"avgChangeRate":-0.007453},{"month":9,"riseRate":0.454545,"avgChangeRate":0.062175},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005789},{"month":11,"riseRate":0.5,"avgChangeRate":0.018834},{"month":12,"riseRate":0.409091,"avgChangeRate":0.027449}],"exchange":"NASDAQ","name":"Corcept Therapeutics","nameEN":"Corcept Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Corcept Therapeutics,CORT,Corcept Therapeutics股票,Corcept Therapeutics股票老虎,Corcept Therapeutics股票老虎国际,Corcept Therapeutics行情,Corcept Therapeutics股票行情,Corcept Therapeutics股价,Corcept Therapeutics股市,Corcept Therapeutics股票价格,Corcept Therapeutics股票交易,Corcept Therapeutics股票购买,Corcept Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Corcept Therapeutics(CORT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Corcept Therapeutics(CORT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction